Smith & Nephew PLC (SNN-N)

He owns Stryker instead. But SNN enjoys a demographic tailwind as Boomers age. Demand will continue to grow.

US Healthcare For knee replacements and implants he likes SNN-N. He does not prefer the ETFs, such as XLV-N, because they hold too broad of an array of companies, including the big drug companies that are under pressure. He would focus on the tool and device space instead.

Has owned it in the past. Primary business in orthopedics. Great company. Last quarter has been mixed. There is speculation that they are buying Boston Scientific. Valuation wise it is OK. Stryker (SYK-N) is taking leadership in the orthopedic space. Longer term he prefers Stryker (SYK-N).

Smith & Nephew or Stryker? Smith: Knows it only marginally. The options S&N were generation aren't attractive enough for him to buy. Stryker: Keep an eye on this. Their robotic surgery is cutting a strong profile in orthopedic surgeries. It's definitely becoming the market leader.

(A Top Pick Aug 11/11. Up 24.13%.) Demand for discretionary medical devices has been affected by the economy. Like many European companies, the valuations are quite low and can have further upside from here.